VIG is indicated or not recommended for
the following conditions:
VIG
Administration
|
| Indicated
|
• |
Inadvertent inoculation
(extensive lesions or some ocular implantations) |
| • |
Eczema vaccinatum
|
| • |
Generalized vaccinia
(if severe or recurrent) |
| • |
Progressive vaccinia
|
Not
Recommended |
• |
Inadvertent inoculation (mild instances) |
| • |
Generalized vaccinia
(mild or limited - most instances) |
| • |
Erythema multiforme
|
| • |
Post-vaccination encephalitis |
| • |
Isolated vaccinia keratitis (may
produce severe corneal opacities) |
|
|
|
|
Concomitant Use with Vaccination
In some instances, VIG was given concomitantly with vaccination to try to “prevent” complications in a susceptible person. Not enough is known about the effectiveness of this use to recommend it.
Dosage
When it was used in the 1950’s-1970’s, the dosage of VIG varied. In general an initial dose of 0.6 ml/kg body weight (about 100mg/kg) was injected intramuscularly and subsequent administration determined by the course of illness. Dosages of the new Intravenous formulations of VIG may vary and will be outlined in the Investigational New Drug (IND) protocols for these products until they are licensed.
In severe cases of eczema vaccinatum and progressive vaccinia as much as 1-10 mg/kg were used. These large doses were split into smaller units, and intramuscularly injected at multiple sites spread out over time.
Frequency of Use
Data from a CDC survey indicates that VIG was administered for these conditions at a rate of 47 uses per 47 million primary vaccinees and 2 uses per million revaccinees.
|
